Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Erasca Inc (ERAS)

Erasca Inc (ERAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,479,758
  • Shares Outstanding, K 309,587
  • Annual Sales, $ 0 K
  • Annual Income, $ -161,650 K
  • EBIT $ -144 M
  • EBITDA $ -150 M
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.65

Options Overview Details

View History
  • Implied Volatility 107.74% (-5.77%)
  • Historical Volatility 134.77%
  • IV Percentile 1%
  • IV Rank 1.14%
  • IV High 1,077.61% on 04/10/25
  • IV Low 96.58% on 03/27/25
  • Expected Move (DTE 15) 2.04 (18.15%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 1,166
  • Volume Avg (30-Day) 3,082
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 32,976
  • Open Int (30-Day) 40,273
  • Expected Range 9.20 to 13.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.11
  • Number of Estimates 6
  • High Estimate -0.10
  • Low Estimate -0.12
  • Prior Year -0.11
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.36 +234.52%
on 01/05/26
11.40 -1.40%
on 02/04/26
+7.65 (+213.09%)
since 01/02/26
3-Month
2.11 +433.97%
on 11/07/25
11.40 -1.40%
on 02/04/26
+8.93 (+386.58%)
since 11/04/25
52-Week
1.01 +1,012.87%
on 04/09/25
11.40 -1.40%
on 02/04/26
+9.46 (+531.46%)
since 02/04/25

Most Recent Stories

More News
Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock?

Erasca (ERAS) has surged 460% over the past year, driven by strong technical momentum. ERAS hit a new 3-year high of $10.92 on Monday. Despite bullish technicals, ERAS has no revenue, is burning cash,...

ERAS : 11.24 (+6.19%)
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 11.24 (+6.19%)
Erasca Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 11.24 (+6.19%)
Erasca Announces Proposed Public Offering of $150 Million of Common Stock

SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 11.24 (+6.19%)
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015...

ERAS : 11.24 (+6.19%)
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 11.24 (+6.19%)
Erasca to Present at the 8th Annual Evercore Healthcare Conference

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 11.24 (+6.19%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

ONCY : 0.9000 (+2.53%)
IMRX : 4.74 (-3.46%)
ALXO : 2.01 (+7.49%)
ERAS : 11.24 (+6.19%)
PRLD : 2.30 (+0.44%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...

ONCY : 0.9000 (+2.53%)
IMRX : 4.74 (-3.46%)
ALXO : 2.01 (+7.49%)
ERAS : 11.24 (+6.19%)
PRLD : 2.30 (+0.44%)
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043  Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001...

ERAS : 11.24 (+6.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 12.53
2nd Resistance Point 11.97
1st Resistance Point 11.60
Last Price 11.24
1st Support Level 10.67
2nd Support Level 10.11
3rd Support Level 9.74

See More

52-Week High 11.40
Last Price 11.24
Fibonacci 61.8% 7.43
Fibonacci 50% 6.20
Fibonacci 38.2% 4.98
52-Week Low 1.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar